Please assess the completion status of the following clinical trial:

Trial Title: Study in Adult Subjects Undergoing Posterolateral Thoracotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females ≥18 years of age.~2. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.~3. Scheduled to undergo chest surgery using either minimally invasive (VATS or robotic-assisted surgery) or open techniques (posterolateral, lateral, or anterior thoracotomy or requiring insertion of an inter-rib spreader/retractor) for a primary thoracic non-infectious indication under general anesthesia.~4. Able to provide informed consent, adhere to the study schedule, and complete all study assessments.~Exclusion Criteria:~1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an acceptable method of birth control. If of childbearing potential, the subject must have a documented negative pregnancy test within 24 hours before surgery.~2. Prior ipsilateral thoracotomy (the likely presence of adhesions will limit ability to perform a precise block guided by thoracoscopy). Note: previous VATS or robotic surgery is permissible.~3. Any planned pleurodesis as part of the surgical procedure.~4. Redo ipsilateral thoracotomy~5. Received bupivacaine or any other local anesthetic within 7 days of screening.~6. Body weight \< 50 kilograms (110 pounds) or a body mass index ≥ 35 kg/m2.~7. History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics or opioids.~8. Previous participation in a liposome bupivacaine study.~9. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.~10. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance.~11. Significant medical conditions (including widely disseminated metastatic disease) or laboratory results that, in the opinion of the investigator, indicate an increased vulnerability to study drugs and procedures.~12. History of coronary or vascular stent placed within the past 3 months (may be extended to 1 year if medically indicated per physician discretion).~13. Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).~14. Severely impaired renal or hepatic function (eg, serum creatinine level \> 2 mg/dL \[176.8 μmol/L\], blood urea nitrogen level \>50 mg/dL \[17.9 mmol/L\], serum aspartate aminotransferase \[AST\] level \>3 times the upper limit of normal \[ULN\], or serum alanine aminotransferase \[ALT\] level \> 3 times ULN).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EXPAREL 20 + 20 (Type: EXPERIMENTAL): 20 mL EXPAREL with 20 mL normal saline
- EXPAREL 20 + 10 (Type: EXPERIMENTAL): 20 mL EXPAREL with 10 mL normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues